US biotech Sirnaomics has won Food and Drug Administration (FDA) approval to test its STP705 treatment, an RNA inference (RNAi) candidate, for bile duct cancer. It has already been trialled for scar-reduction treatment. Sirnaomics said STP705 downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. The company is also working on the development of RNAi treatments that target other types of cancer including lung cancer, prostate cancer and pancreatic cancer. It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US, Europe and China where it has a partnership with Guangzhou Xiangxue Pharma.
US biotech Sirnaomics has won Food and Drug Administration (FDA) approval to test its STP705 treatment, an RNA inference (RNAi) candidate, for bile duct cancer. It has already been trialled for scar-reduction treatment. Sirnaomics said STP705 downregulated cancer-associated fibroblast activity in and around a tumour which restricted its growth. Sirnaomics said it had been working on RNAi treatments for more than a decade. It raised $25m from Chinese investors in June to continue its work. Two clinical trials are planned for later this year in the US, Europe and China where it has a partnership with Guangzhou Xiangxue Pharma.